**Amendments To The Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. (Original) A compound of formula (I);



(I)

wherein:

Y is phenyl, unsubstituted or substituted with one, two or three substituents;

$R^1$ is selected from hydrogen, $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, or halosubstituted$C_{1-6}$ alkyl;

$R^2$ is $(CH_2)_mR^3$ where m is 0 or 1;

or $R^1$ and $R^2$ together with N to which they are attached form an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl ring;

$R^3$ is an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl group, an unsubstituted or substituted $C_{3-8}$ cycloalkyl group, an unsubstituted or substituted straight or branched $C_{1-10}$ alkyl, an unsubstituted or substituted $C_{5-7}$ cycloalkenyl, $R^5$ or $R^3$ is an optionally substituted 5- to 6-membered aromatic heterocyclyl group, or group A:



(A)

$R^4$ is selected from hydrogen, $C_{1-6}$ alkyl, $C_{3-6}$ cycloalkyl, or halosubstituted$C_{1-6}$ alkyl, $COCH_3$, or $SO_2Me$;

$R^5$ is



wherein p is 0, 1 or 2, and X is $CH_2$, O, S, SO or $SO_2$;

$R^6$ is halo, an substituted or unsubstituted $(C_{1-6})$alkyl, substituted or unsubstituted $(C_{3-6})$cycloalkyl, or a 4- to 7- membered non aromatic heterocyclic group and $R^{10}$ is hydrogen or $R^{10}$ is halo, an substituted or unsubstituted $(C_{1-6})$alkyl, substituted or unsubstituted $(C_{3-6})$cycloalkyl, or a 4- to 7- membered non aromatic heterocyclic group and $R^6$ is hydrogen:

$R^7$ is OH, $C_{1-6}$alkoxy, $NR^{8a}R^{8b}$, $NHCOR^9$, $NHSO_2R^9$, $SOqR^9$;

$R^{8a}$ is H or $C_{1-6}$alkyl;

$R^{8b}$ is H or $C_{1-6}$alkyl;

$R^9$ is $C_{1-6}$alkyl;

$R^{12}$ is hydrogen or $C_{1-6}$alkyl;

q is 0, 1 or 2;

Ra can be independently selected from hydrogen, fluoro, chloro or trifluoromethyl;

Rb can be independently be selected from hydrogen, $C_{1-6}$ alkyl, $C_{1-6}$ alkoxy, halo$C_{1-6}$ alkoxy, hydroxy, cyano, halo, sulfonyl, $CONH_2$, COOH or $NHCOOC_{1-6}$alkyl;

or a pharmaceutically acceptable derivative thereof.

2. (Original) A compound as claimed in Claim 1 wherein the compound of formula (I) is a compound of formula (Ia):



(Ia)

wherein;

$R^3$ is an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl group, an unsubstituted or substituted $C_{3-8}$ cycloalkyl group or a straight or branched $C_{1-6}$alkyl group;

$R^6$ is isopropyl, cyclopropyl, trifluoromethyl, *t*-butyl or cyclopentyl;

$R^{11}$ is selected from halo, cyano, methyl, trifluoromethyl, methoxy or trifluoromethoxy;

$R^{12}$ is hydrogen or $C_{1-6}$alkyl;

d is 0, 1, 2 or 3;

m is 0 or 1;

or a pharmaceutically acceptable derivative thereof.

3. (Original) A compound as claimed in Claim 1 wherein the compound of formula (I) is a compound of formula (Ib):



(Ib)

wherein;

$R^3$ is an optionally substituted 5- to 6- membered aromatic heterocyclyl group, or group A;

$R^6$ is isopropyl, cyclopropyl, trifluoromethyl, *t*-butyl or cyclopentyl;

$R^{11}$ is selected from halo, cyano, methyl, trifluoromethyl, methoxy or trifluoromethoxy;

$R^{12}$ is hydrogen or $C_{1-6}$alkyl;

d is 0, 1, 2 or 3;

m is 0 or 1;

or a pharmaceutically acceptable derivative thereof.

4. (Original) A compound as claimed in Claim 1 wherein the compound of formula (I) is a compound of formula (Ic):



(Ic)

wherein;

$R^1$ and $R^2$ together with N to which they are attached form an unsubstituted or substituted 4- to 8- membered non-aromatic heterocyclyl ring;

$R^6$ is isopropyl, cyclopropyl, trifluoromethyl, *t*-butyl or cyclopentyl;

$R^{11}$ is selected from halo, cyano, methyl, trifluoromethyl, methoxy or trifluoromethoxy;

$R^{12}$ is hydrogen or $C_{1-6}$alkyl;

d is 0, 1, 2 or 3;

or a pharmaceutically acceptable derivatives thereof.

5. Canceled.

6. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in ~~any one of~~ claims 1 ~~to 5 or 2~~ or a pharmaceutically acceptable derivative thereof and a pharmaceutical carrier or diluent thereof.

7. (Original) A pharmaceutical composition as claimed in claim 6 further comprising a second theraputic agent.

8. (Original) A pharmaceutical composition as claimed in claim 7 wherein the second therapeutic agent is a PDE4 inhibitor.

9. (Currently Amended) A method of treating a mammal suffering from a condition which is mediated by the activity of cannabinoid 2 receptors which comprises administering to said subject a therapeutically effective amount of a compound of formula (I) as claimed in ~~any one of~~ claims 1 ~~to 5~~ or a pharmaceutically acceptable derivative thereof.

10. (Currently Amended) A compound of formula (I) as claimed in ~~any one of~~ claims 1 ~~to 5~~ or a pharmaceutically acceptable derivative thereof for use as a medicament in the treatment of pain.

11. (New) A pharmaceutical composition as claimed in claim 7 wherein the second therapeutic agent is a Cox-2 inhibitor.

12. (New) The method of claim 9 wherein the condition is selected from an immune disorder, an inflammatory disorder, pain, rheumatoid arthritis, multiple sclerosis, osteoarthritis or osteoporosis.